Quazinone (Dozonone) is a cardiotonic and vasodilator drug which was developed and marketed in the 1980s for the treatment of heart disease.[1][2][3][4][5] It acts as a selective PDE3 inhibitor.[6][7] It is no longer available.[1]
Synthesis
[8]
See also
References
- ↑ 1.0 1.1 David J. Triggle (1996). Dictionary of Pharmacological Agents. Boca Raton: Chapman & Hall/CRC. ISBN 0-412-46630-9.
- ↑ Eigenmann R, Gerold M, Holck M (1984). "Cardiovascular profile of Ro 13-6438, a novel positive inotropic agent with vasodilating properties". Journal of Cardiovascular Pharmacology 6 (3): 511–9. PMID 6202980.
- ↑ Holck M, Thorens S, Muggli R, Eigenmann R (1984). "Studies on the mechanism of positive inotropic activity of Ro 13-6438, a structurally novel cardiotonic agent with vasodilating properties". Journal of Cardiovascular Pharmacology 6 (3): 520–30. PMID 6202981.
- ↑ Belz GG, Stern HC, Butzer R (1985). "Dose-response following single administrations of a new cardiac performance enhancer RO 13-6438 in normal volunteers". Journal of Cardiovascular Pharmacology 7 (1): 86–90. PMID 2580156.
- ↑ Daly PA, Chatterjee K, Viquerat CE, et al. (June 1985). "RO13-6438, a new inotrope-vasodilator: systemic and coronary hemodynamic effects in congestive heart failure". The American Journal of Cardiology 55 (13 Pt 1): 1539–44. PMID 4003296.
- ↑ Osinski MT, Schrör K (August 2000). "Inhibition of platelet-derived growth factor-induced mitogenesis by phosphodiesterase 3 inhibitors: role of protein kinase A in vascular smooth muscle cell mitogenesis". Biochemical Pharmacology 60 (3): 381–7. doi:10.1016/S0006-2952(00)00328-2. PMID 10856433.
- ↑ Denis D, Riendeau D (February 1999). "Phosphodiesterase 4-dependent regulation of cyclic AMP levels and leukotriene B4 biosynthesis in human polymorphonuclear leukocytes". European Journal of Pharmacology 367 (2-3): 343–50. doi:10.1016/S0014-2999(98)00987-X. PMID 10079010.
- ↑ Chodnekar, M. S.; Kaiser, A.; 1981, U.S. Patent 4,256,748
